Espansione Group, an Italian company specialising in ophthalmic devices, has unveiled a breakthrough in the field of dry eye diagnostics with their new artificial intelligence-driven software, MeiboMetrics. This innovative algorithm is designed to advance the segmentation and quantitative measurement of meibomian glands, key structures in the eyelids responsible for maintaining eye health by secreting oils to the eye’s surface.
Developed in collaboration with the Institute of Biomedical and Neural Engineering at Reykjavik University, the project commenced in early 2023. It marks a significant step forward in eye care technology by providing a sophisticated bio-imaging approach to analyse and assess meibomian glands.
Paolo Gargiulo, a full professor at Reykjavik University and a pivotal figure in the institute's development, highlighted the transformative potential of MeiboMetrics in a recent statement. He noted that the software furnishes a detailed quantitative evaluation of dry eye conditions, purportedly pushing the boundaries of current technological capabilities in ophthalmology.
The core functionality of MeiboMetrics lies in its ability to generate precise data pertaining to the length, width, and area of individual meibomian glands. By integrating AI technology, it not only identifies and segments these glands with high accuracy but also cross-references them with an extensive training dataset. This feature ensures enhanced precision, reduces manual error, and promises consistent results across examinations, thereby simplifying the clinical workflow for eyecare professionals.
An important offering of Espansione Group, MeiboMetrics' impact is set to be broadened further as it becomes available on the me-check Pro platform and other related software come 2025. This release is part of the company’s broader portfolio, which includes a range of devices designed for various ophthalmic conditions. Their innovative products, such as the eye-light and meibomask devices, utilise technologies like Light Modulation Low-Level Light Therapy (LM LLLT) and Optimal Power Energy for treating conditions such as dry age-related macular degeneration and meibomian gland dysfunction.
The AI-powered advancements promise a leap towards more efficient and error-free diagnosis, potentially setting a new standard in the management of dry eye disease and related conditions. This launch reflects the ongoing commitment of Espansione Group and its partners to leverage cutting-edge technology for enhanced healthcare solutions.
Source: Noah Wire Services